Vandetanib therapy in medullary thyroid cancer.
-
Grabowski, P. [1] [2] ; Briest, F. [1] [3] ; Baum, R.P. [4] ; Zaknun, J.J. [4] ; Kulkarni, H.R. [4] ; Zeitz, M. [1] ; Hoersch, D. [2]
-
[1] Charité-Universitätsmedizin Berlin, CBF, Medical Clinic I, Dept. of Gastroenterology, Infectious Diseases, Rheumatology, Berlin, Germany
-
[2] Department of Gastroenterology/Endocrinology ENETS Center of Excellence, Zentralklinik Bad Berka, Germany
-
[3] Freie Universität Berlin, Institut für Chemie und Biochemie, Berlin, Germany
-
[4] THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Center for Neuroendocrine Tumours Bad Berka – ENETS Center of Excellence, Zentralklinik Bad Berka, Germany
-
- Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 48, Nº. 11, 2012, págs. 723-733
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
The U.S. Food and Drug Administration (FDA) approved vandetanib in April 2011 for the treatment of unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). In Europe it was approved in March 2012, but only for the treatment of aggressive and symptomatic MTC. This small molecule is a tyrosine kinase inhibitor of several growth factors involved in cellular proliferation and angiogenesis, including the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor receptors 2 and 3 (VEGFR-2, VEGFR-3). In addition, vandetanib is an inhibitor of the RET (rearranged during transfection) gene, a proto-oncogene often mutated in familial MTC. Since MTC is a rare disease, for which no previous medical therapies are approved, vandetanib is the first drug shown to be effective in a large phase III trial treating patients with metastatic or locally advanced MTC. Common adverse events are diarrhea, nausea, hypertension, headache and QT prolongation that are manageable and are commonly outweighed by the benefits of vandetanib in terms of delaying disease progression and inducing tumor response.
